Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 13 (Search time: 0.002 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment
Kim, D.
;
Kim, D.
;
Kim, S.
;
Goh, H.
;
Pane, F.
;
Hughes, T.
;
Radich, J.
;
Lin, P.
;
Saglio, G.
;
Branford, S.
;
Martinelli, G.
;
Soverini, S.
;
Hochhaus, A.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2016
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Deininger, M.
;
Hodgson, J.
;
Shah, N.
;
Cortes, J.
;
Kim, D.
;
Nicolini, F.
;
Talpaz, M.
;
Baccarani, M.
;
Müller, M.
;
Li, J.
;
Parker, W.
;
Lustgarten, S.
;
Clackson, T.
;
Haluska, F.
;
Guilhot, F.
;
Kantarjian, H.
;
Soverini, S.
;
Hochhaus, A.
;
Hughes, T.
;
Rivera, V.
;
et al.
2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Stein, A.
;
Martinelli, G.
;
Hughes, T.
;
Muller, M.
;
Beppu, L.
;
Gottardi, E.
;
Branford, S.
;
Soverini, S.
;
Woodman, R.
;
Hochhaus, A.
;
Kim, D.
;
Saglio, G.
;
Radich, J.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2015
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Quintás-Cardama, A.
;
Mauro, M.
;
Kim, D.
;
Lipton, J.
;
Bradley-Garelik, M.
;
Ukropec, J.
;
Hochhaus, A.
2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
Hochhaus, A.
;
Muller, M.
;
Radich, J.
;
Branford, S.
;
Kantarjian, H.
;
Hanfstein, B.
;
Rousselot, P.
;
Kim, D.
;
Lipton, J.
;
Bleickhardt, E.
;
Lambert, A.
;
Hughes, T.
2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R.
;
Hochhaus, A.
;
Hughes, T.
;
Clark, R.
;
Etienne, G.
;
Kim, D.
;
Flinn, I.
;
Kurokawa, M.
;
Moiraghi, B.
;
Yu, R.
;
Blakesley, R.
;
Gallagher, N.
;
Saglio, G.
;
Kantarjian, H.
2010
Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia
Saglio, G.
;
Kim, D.
;
Issaragrisil, S.
;
le Coutre, P.
;
Etienne, G.
;
Lobo, C.
;
Pasquini, R.
;
Clark, R.
;
Hochhaus, A.
;
Hughes, T.
;
Gallagher, N.
;
Hoenekopp, A.
;
Haque, A.
;
Dong, M.
;
Larson, R.
;
Kantarjian, H.
Discover
Author
8
Saglio, G.
7
Kantarjian, H.
7
Larson, R.
6
Cortes, J.
6
Radich, J.
5
Martinelli, G.
4
Baccarani, M.
4
Branford, S.
4
Lipton, J.
4
Muller, M.
.
next >
Subject
7
Humans
7
Pyrimidines
6
Benzamides
6
Imatinib Mesylate
6
Piperazines
5
Adult
5
Aged
5
Antineoplastic Agents
5
Fusion Proteins, bcr-abl
5
Middle Aged
.
next >
Date issued
1
2016
1
2015
3
2013
1
2012
1
2011
2
2010
3
2009
1
2008